ORYZON to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026

What happened

Oryzon Genomics announced updated positive early-stage clinical data for iadademstat, its selective LSD1 inhibitor, in acute myeloid leukemia and myeloproliferative neoplasms. It plans to present the findings in poster sessions at the ASH annual meeting in New Orleans, December 12–15, 2026.

Confirmed

Global impact / market context

The announcement may strengthen the case for further testing iadademstat with standard treatment in blood cancers. If later trials confirm benefit and acceptable safety, successful development could support future drug revenue; for now, the evidence is early-stage and does not establish that the treatment works.

Analyst inference

Oryzon says the data support moving toward a planned Phase III trial in newly diagnosed acute myeloid leukemia. Phase III is a large, later-stage study intended to test a treatment more fully. The supplied article gives no trial results beyond the company’s positive description or commercial outlook.

Analyst inference

What to watch

1. At the December 12–15 ASH meeting, review the poster data for measured treatment outcomes and safety details in the leukemia and myeloproliferative disease studies. Analyst inference
2. Check whether Oryzon advances the planned ALICE-3 Phase III trial in newly diagnosed acute myeloid leukemia, and whether its design reflects the earlier dose-selection rationale. Analyst inference
3. Look for further evidence on iadademstat combined with standard treatment, especially in patient groups described as responding poorly to current treatments; the article provides no quantified results. Analyst inference

Evidence

• globenewswire.com